Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Sophia Kessabi"'
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: External reference pricing (ERP) is used to set pharmaceutical prices to improve affordability, but its application may have negative consequences on patient access—thus, equity—across countries and on global innovation. With the Unit
Externí odkaz:
https://doaj.org/article/fb898be743794b6599952235fec2ea22
Autor:
Katharine Batt, Sophia Kessabi, Parth Vashi, Wei Gao, Rajeev Ayyagari, Robert Klamroth, Zhiwen Yao, Celine Deschaseaux, Yao Wang
Publikováno v:
Journal of Blood Medicine
Katharine Batt,1 Wei Gao,2 Rajeev Ayyagari,2 Céline Deschaseaux,3 Parth B Vashi,4 Zhiwen Yao,2 Yao Wang,2 Sophia Kessabi,3 Robert Klamroth51Department of Internal Medicine, Section on Hematology/Medical Oncology, Wake Forest University Baptist Medic
Publikováno v:
The Patient
Introduction Prophylactic treatment of severe hemophilia A is burdensome, requiring frequent intravenous injections. Extended half-life (EHL) factor VIII replacement therapies offer longer intervals between infusions while still meeting efficacy and
Publikováno v:
Blood. 126:4748-4748
Background: Iron chelation therapy (ICT) is important for chronic conditions where blood transfusions are an essential therapy (eg transfusion-dependent thalassemia [TDT], sickle-cell disease and myelodysplastic syndromes), to avoid serious long-term
Publikováno v:
A39. PROGRAMATIC ISSUES IN THE CARE OF PATIENTS WITH COPD.
Publikováno v:
Plat, A, Penning-Van Beest, F, Kessabi, S, Groot, M & Herings, R 2009, ' Change of initial oral antidiabetic therapy in type 2 diabetic patients ', Pharmacy World and Science, vol. 31, no. 6, pp. 622-626 . https://doi.org/10.1007/s11096-009-9321-0
Pharmacy World and Science, 31(6), 622-626. Kluwer Academic Publishers
Pharmacy World and Science, 31(6), 622-626. Kluwer Academic Publishers
Objective To explore the 'real-life' therapy of type 2 diabetes mellitus with oral antidiabetic drugs (OADs). Methods From the PHARMO Record Linkage System comprising linked drug dispensing and clinical laboratory data from approximately 2.5 million
Autor:
Ron M. C. Herings, Sjoukje van der Bij, Fernie J. A. Penning-van Beest, Martijn Groot, Sophia Kessabi, JA Erkens
Publikováno v:
Current Medical Research and Opinion, 24(9), 2523-2529. Taylor and Francis Ltd.
Penning-van Beest, F J A, van der Bij, S, Erkens, J A, Kessabi, S, Groot, M & Herings, R M C 2008, ' Effect of non-persistent use of oral glucose-lowering drugs on HbA 1c goal attainment ', Current Medical Research and Opinion, vol. 24, no. 9, pp. 2523-2529 . https://doi.org/10.1185/03007990802336335
Penning-van Beest, F J A, van der Bij, S, Erkens, J A, Kessabi, S, Groot, M & Herings, R M C 2008, ' Effect of non-persistent use of oral glucose-lowering drugs on HbA 1c goal attainment ', Current Medical Research and Opinion, vol. 24, no. 9, pp. 2523-2529 . https://doi.org/10.1185/03007990802336335
Objectives: The aim of this study was to quantify the effect of non-persistence with oral glucose-lowering drugs (OGLD) on HbA1c goal attainment (1c ≥7% and at least one HbA1c measurement in the period of 6-12 months after treatment onset were incl
Autor:
Martijn Groot, S van der Bij, JA Erkens, Fja Penning-van Beest, Sophia Kessabi, J Koerselman, Rmc Herings
Publikováno v:
Value in Health. 10(6)
Autor:
J Koerselman, Fja Penning-van Beest, S van der Bij, JA Erkens, Sophia Kessabi, Martijn Groot, Rmc Herings
Publikováno v:
Value in Health. 10:A276
DETERMINANTS OF STOPPINGTREATMENTWITH ORAL ANTIDIABETIC DRUGS IN DAILY CLINICAL PRACTICE Koerselman J, van der Bij S, Erkens JA, Kessabi S, Groot MT, Penning-van Beest FJA, Herings RMC PHARMO Institute, Utrecht, Utrecht,The Netherlands, Novartis Phar
Publikováno v:
PharmacoEconomics. 21:681